Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Biofrontera Inc.

Get SEC filing alerts via email and in your feed for Biofrontera Inc.

BFRI BFRIW

Biofrontera Inc.

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in dermatology, primarily commercializing photodynamic therapy (PDT) products for treating actinic keratosis. Its core offerings include the prescription drug Ameluz® and RhodoLED® lamps, used together for targeted skin lesion treatment. Biofrontera markets these products directly to dermatology providers in the U.S., leveraging exclusive licensing agreements and focusing on clinical development, regulatory compliance, and reimbursement to support adoption.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Biofrontera Inc.

1
1
Biofrontera Inc. Biofrontera Inc. Reports 17.4% Revenue Growth to $10.1 Million in Q1 2026

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Biofrontera Inc. Biofrontera Inc. Reports $10.5 Million Net Loss and $41.7 Million Revenue for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Biofrontera Inc. Biofrontera Inc. Reports Q3 2025 Financial Results with Increased Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Biofrontera Inc. Biofrontera Reports $5.3 Million Net Loss in Q2 2025, Revenue Increases 15.3%

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Biofrontera Inc. Biofrontera Reports Q1 2025 Financial Results with Improved Net Loss and Revenue Growth

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Biofrontera Inc. Biofrontera Inc. Reports $17.8 Million Net Loss and $37.3 Million Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Biofrontera Inc. Biofrontera Reports Q3 2024 Financial Results, Net Loss Improves Despite Revenue Growth

Via official filing (AI summary) | over 1 year ago | 0 comments